Class action lawsuit filed against Capricor Therapeutics for securities fraud

A securities fraud class action has been initiated against Capricor Therapeutics, Inc. The law firm Levi & Korsinsky recently alerted investors of the deadline for taking action, which is September 15, 2025. The lawsuit accuses Capricor of violating federal securities laws by allegedly making false and misleading statements regarding the Company’s business practices and financial performance.

Investors who purchased shares of Capricor Therapeutics between August 26, 2024, and July 10, 2025, may be eligible to participate in the class action lawsuit. The complaint alleges that Capricor failed to disclose crucial information to investors, causing them to suffer losses when the truth about the Company’s operations came to light.

According to the lawsuit, Capricor misled investors about the success of its clinical trials and the prospects for its flagship product. The Company is accused of overstating the effectiveness of its potential treatments for certain medical conditions, leading investors to believe that Capricor was on the brink of commercial success.

However, it is alleged that Capricor’s statements were false and misleading. The Company is accused of exaggerating the results of its clinical trials and failing to disclose negative information that would have affected investors’ decisions. As a result, shareholders who relied on Capricor’s statements suffered financial losses when the truth was revealed.

The class action lawsuit seeks to hold Capricor accountable for its alleged misconduct and to compensate investors for their losses. Levi & Korsinsky are encouraging investors who purchased Capricor Therapeutics stock during the specified time frame to join the lawsuit before the September 15, 2025, deadline.

Investors who believe they have been affected by Capricor’s alleged securities fraud are urged to contact Levi & Korsinsky to participate in the class action lawsuit. The law firm specializes in representing shareholders who have been harmed by fraudulent business practices and securities violations.

Securities fraud can have serious consequences for investors, leading to substantial financial losses and damage to their portfolios. By holding companies accountable for their actions and seeking compensation for affected shareholders, class action lawsuits play an essential role in promoting transparency and accountability in the financial markets.

In conclusion, the securities fraud class action filed against Capricor Therapeutics highlights the importance of protecting investors from misleading and deceptive practices in the business world. Investors who believe they have been harmed by Capricor’s alleged misconduct are encouraged to take action and seek justice through the legal system.